The Food and Drug Administration proposed new rules that will provide pharmaceutical companies more latitude in promoting off-label uses of medicines, biologics and medical devices.
The Food and Drug Administration proposed new rules that will provide pharmaceutical companies more latitude in promoting off-label uses of medicines, biologics and medical devices.
If the rules are finalized and implemented as a provision of the FDA Modernization Act of 1997, sales reps will be empowered to share information such as peer-reviewed journal articles about off-label uses with health care practitioners, pharmacy benefit managers, health insurance issuers, group health plans and state and federal agencies.
In the past, pharmaceutical companies had to wait until the FDA approved a supplemental application before they could disseminate even reliable information about unapproved uses.
The new rules specify that off-label, unapproved information can only be disseminated under certain conditions: Companies must study the unapproved uses and have submitted, or made plans to submit, applications for formal FDA approval, and the information must be reliable and balanced. It may be an unabridged reprint or copy of a peer-reviewed scientific or medical journal article, or an unabridged reference publication about a clinical investigation that is considered scientifically sound.
The unapproved uses must not pose a significant risk to the public health, be false or misleading or have been derived without permission from clinical research conducted by another pharmaceutical manufacturer. Companies must also include certain disclosures with the information, including official labeling, a bibliography of other articles pertaining to the new use and a statement indicating that the new use has not been approved by the FDA.
To keep pharmaceutical companies motivated to acquire official FDA approval, companies will also have to submit a copy of the information to the FDA within 60 days prior to disseminating the information. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.